Adult patients with a type of cancer known as Burkitt lymphoma had excellent long-term survival rates—upwards of 90 percent—following treatment with low-intensity chemotherapy regimens, according to a new clinical trial finding. Wyndham H. Wilson M.D. Ph.D., head of NCI’s Lymphoma Therapeutics Section, and colleagues conducted the trial at NIH’s Clinical Center. Read more here.
Study mentioned: Dunleavy K, et al. Low-Intensity Therapy in Adult Burkitt Lymphoma. N Engl J Med 2013; 369:1915-1925.
No comments:
Post a Comment